IMARC Group, a leading market research company, has recently released a report titled “Non-Alcoholic Steatohepatitis (NASH) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028” The study provides a detailed analysis of the industry, including the non-alcoholic steatohepatitis (NASH) market size, share, trends and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

How big is the Non-Alcoholic Steatohepatitis (NASH) Market?

The global non-alcoholic steatohepatitis (NASH) market size reached US$ 1.21 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.55 Billion by 2028, exhibiting a growth rate (CAGR) of 27.70% during 2023-2028.

What is Non-Alcoholic Steatohepatitis (NASH)?

NASH, or non-alcoholic steatohepatitis, is caused by insulin resistance, overweight, and metabolic syndrome. Some of the common symptoms include fatigue, weakness, weight loss, jaundice, itchy skin, spider veins, enlarged liver, lack of concentration, fluid accumulation, and abdominal discomfort. Diagnosis of NASH involves physical examination, blood tests, liver biopsy, MRI, ultrasound, CT scan, etc. Treatment options encompass medication, liver transplant, and lifestyle changes, including exercise and healthy diets. These methods aim to reduce liver fat, improve function, minimize inflammation, manage obesity and high blood pressure, etc.

Request for a sample copy of this report: https://www.imarcgroup.com/non-alcoholic-steatohepatitis-market/requestsample

What are the growth prospects and trends in the non-alcoholic steatohepatitis (NASH) industry?

The escalating prevalence of this condition, owing to genetics, sedentary lifestyles, and unhealthy eating habits of individuals, is primarily driving the non-alcoholic steatohepatitis (NASH) market. Besides this, patients widely adopt advanced treatment procedures to alleviate symptoms, increase lifespan, and enhance overall well-being, which is further augmenting the market growth. Moreover, the growing awareness among the masses towards early diagnosis and therapies to reduce healthcare expenses, avoid liver transplants, and prevent complications, such as high blood pressure levels, cardiovascular diseases, cancer, cirrhosis, etc., is also catalyzing the global market. Apart from this, the elevating requirement for non-invasive imaging techniques, including MRI and TE, to provide patient comfort, better compliance, reduced complications, enhanced clinical outcomes, etc., is acting as another significant growth-inducing factor. Additionally, the rising integration of artificial intelligence for facilitating personalized treatments, accurate diagnosis, and disease progression prediction and the launch of several policies by government bodies supporting access to high-quality treatment and advanced therapeutics are expected to bolster the non-alcoholic steatohepatitis (NASH) market in the coming years.

What is included in market segmentation?

The report has segmented the market into the following categories:

Drug Type Insights:

• Vitamin E and Pioglitazone
• Ocaliva
• Elafibranor
• Selonsertib
• Cenicriviroc
• Others
  
  

Disease Cause Insights:

• Hypertension
• Heart Disease
• High Blood Lipid
• Type 2 Diabetes
• Obesity
  
  

Sales Channel Insights:

• Hospital Pharmacy
• Online Providers
• Retail Pharmacy
  
  

End User Insights:

• Hospitals
• Clinics
• Homecare Settings
  
  

Market Breakup by Region:

• North America (United States, Canada)
• Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa
  
  

Who are the key players operating in the industry?

The report covers the major market players including:

• Algernon Pharmaceuticals
• Galmed Pharmaceuticals Ltd
• Intercept Pharmaceuticals Inc.
• Zydus Lifesciences Limited
  
  

Ask Analyst for Sample Report: https://www.imarcgroup.com/request?type=report&id=7397&flag=C

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

Email: sales@imarcgroup.com

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Address: 134 N 4th St. Brooklyn, NY 11249, USA 

Follow us on Twitter: @imarcglobal